{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:33:31Z","timestamp":1707525211026},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,15]]},"DOI":"10.7759\/cureus.43534","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T17:18:29Z","timestamp":1692119909000},"source":"Crossref","is-referenced-by-count":0,"title":["In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study"],"prefix":"10.7759","author":[{"given":"Ioannis D","family":"Passos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimochristos","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areti","family":"Katsouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios E","family":"Papavasileiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Galatas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Tzitzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Mpakosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mironidou- Tzouveleki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3181b8afcf","article-title":"Triple-negative breast cancer: a short review","volume":"33","author":"Elias AD","year":"2010","unstructured":"Elias AD. Triple-negative breast cancer: a short review. Am J Clin Oncol. 2010, 33:637-45. 10.1097\/COC.0b013e3181b8afcf","journal-title":"Am J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-1022-2","article-title":"Bcl-2 antigen expression in luminal A and triple-negative breast cancer","volume":"34","author":"Esc\u00f3rcio-Dourado CS","year":"2017","unstructured":"Esc\u00f3rcio-Dourado CS, Martins LM, Simpl\u00edcio-Revoredo CM, et al.. Bcl-2 antigen expression in luminal A and triple-negative breast cancer. Med Oncol. 2017, 34:161. 10.1007\/s12032-017-1022-2","journal-title":"Med Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.145","article-title":"Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer","volume":"23","author":"Thike AA","year":"2010","unstructured":"Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol. 2010, 23:123-33. 10.1038\/modpathol.2009.145","journal-title":"Mod Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70074-8","article-title":"Triple-negative breast cancer: therapeutic options","volume":"8","author":"Cleator S","year":"2007","unstructured":"Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8:235-44. 10.1016\/S1470-2045(07)70074-8","journal-title":"Lancet Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28914","article-title":"Subtyping of triple-negative breast cancer: implications for therapy","volume":"121","author":"Abramson VG","year":"2015","unstructured":"Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015, 121:8-16. 10.1002\/cncr.28914","journal-title":"Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-017-4434-y","article-title":"Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European women","volume":"166","author":"Corsini C","year":"2017","unstructured":"Corsini C, Henouda S, Nejima DB, et al.. Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European women. Breast Cancer Res Treat. 2017, 166:631-9. 10.1007\/s10549-017-4434-y","journal-title":"Breast Cancer Res Treat"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-010-0957-x","article-title":"Characteristics of triple-negative breast cancer","volume":"137","author":"de Ruijter TC","year":"2011","unstructured":"de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011, 137:183-92. 10.1007\/s00432-010-0957-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.05.003","article-title":"The management of early-stage and metastatic triple-negative breast cancer: a review","volume":"27","author":"Anders CK","year":"2013","unstructured":"Anders CK, Zagar TM, Carey LA. The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am. 2013, 27:737-49. 10.1016\/j.hoc.2013.05.003","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14731","article-title":"Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies","volume":"8","author":"Ocana A","year":"2017","unstructured":"Ocana A, Pandiella A. Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget. 2017, 8:22218-34. 10.18632\/oncotarget.14731","journal-title":"Oncotarget"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0000000000000033","article-title":"Neoadjuvant chemotherapy in breast cancer: what questions remain?","volume":"8","author":"Sulpher J","year":"2014","unstructured":"Sulpher J, Dent R, Dent S. Neoadjuvant chemotherapy in breast cancer: what questions remain?. Curr Opin Support Palliat Care. 2014, 8:59-63. 10.1097\/SPC.0000000000000033","journal-title":"Curr Opin Support Palliat Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1159\/000478087","article-title":"Extended adjuvant chemotherapy in triple-negative breast cancer","volume":"12","author":"Locatelli MA","year":"2017","unstructured":"Locatelli MA, Curigliano G, Eniu A. Extended adjuvant chemotherapy in triple-negative breast cancer. Breast Care (Basel). 2017, 12:152-8. 10.1159\/000478087","journal-title":"Breast Care (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds193","article-title":"Neoadjuvant treatments for triple-negative breast cancer (TNBC)","volume":"23","author":"von Minckwitz G","year":"2012","unstructured":"von Minckwitz G, Martin M. Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol. 2012, 23:vi35-9. 10.1093\/annonc\/mds193","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.919072","article-title":"Progress and prospect of immunotherapy for triple-negative breast cancer","volume":"12","author":"Luo C","year":"2022","unstructured":"Luo C, Wang P, He S, Zhu J, Shi Y, Wang J. Progress and prospect of immunotherapy for triple-negative breast cancer. Front Oncol. 2022, 12:10.3389\/fonc.2022.919072","journal-title":"Front Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1021\/jm5012337","article-title":"In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer","volume":"57","author":"Frik M","year":"2014","unstructured":"Frik M, Mart\u00ednez A, Elie BT, et al.. In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer. J Med Chem. 2014, 57:9995-10012. 10.1021\/jm5012337","journal-title":"J Med Chem"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-120","article-title":"A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease","volume":"12","author":"Kaur P","year":"2012","unstructured":"Kaur P, Nagaraja GM, Zheng H, Gizachew D, Galukande M, Krishnan S, Asea A. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer. 2012, 12:120. 10.1186\/1471-2407-12-120","journal-title":"BMC Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-3-417","article-title":"Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines","volume":"3","author":"Terashima M","year":"2014","unstructured":"Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K. Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. Springerplus. 2014, 3:417. 10.1186\/2193-1801-3-417","journal-title":"Springerplus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2606","article-title":"Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo","volume":"12","author":"Gr\u00fcndker C","year":"2010","unstructured":"Gr\u00fcndker C, F\u00f6st C, Fister S, Nolte N, G\u00fcnthert AR, Emons G. Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo. Breast Cancer Res. 2010, 12:R49. 10.1186\/bcr2606","journal-title":"Breast Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.2013.0047","article-title":"In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models","volume":"24","author":"Johnson KP","year":"2013","unstructured":"Johnson KP, Yearby LA, Stoute D, et al.. In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models. J Health Care Poor Underserved. 2013, 24:104-11. 10.1353\/hpu.2013.0047","journal-title":"J Health Care Poor Underserved"},{"key":"ref19","article-title":"Bosutinib reduces the efficacy of dasatinib in triple-negative breast cancer cell lines","volume":"34","author":"Tarpley M","year":"2014","unstructured":"Tarpley M, Abdissa TT, Johnson GL, Scott JE. Bosutinib reduces the efficacy of dasatinib in triple-negative breast cancer cell lines. Anticancer Res. 2014, 34:1629-35.","journal-title":"Anticancer Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0700","article-title":"Activity of a novel Hec1-targeted anticancer compound against breast cancer cell lines in vitro and in vivo","volume":"13","author":"Huang LY","year":"2014","unstructured":"Huang LY, Chang CC, Lee YS, et al.. Activity of a novel Hec1-targeted anticancer compound against breast cancer cell lines in vitro and in vivo. Mol Cancer Ther. 2014, 13:1419-30. 10.1158\/1535-7163.MCT-13-0700","journal-title":"Mol Cancer Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00872.x","article-title":"Animal research: reporting in vivo experiments: the ARRIVE guidelines","volume":"160","author":"Kilkenny C","year":"2010","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010, 160:1577-9. 10.1111\/j.1476-5381.2010.00872.x","journal-title":"Br J Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00873.x","article-title":"Guidelines for reporting experiments involving animals: the ARRIVE guidelines","volume":"160","author":"McGrath JC","year":"2010","unstructured":"McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL. Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol. 2010, 160:1573-6. 10.1111\/j.1476-5381.2010.00873.x","journal-title":"Br J Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/laban.254","article-title":"Estimation of rat mammary tumor volume using caliper and ultrasonography measurements","volume":"42","author":"Faustino-Rocha A","year":"2013","unstructured":"Faustino-Rocha A, Oliveira PA, Pinho-Oliveira J, et al.. Estimation of rat mammary tumor volume using caliper and ultrasonography measurements. Lab Anim (NY). 2013, 42:217-24. 10.1038\/laban.254","journal-title":"Lab Anim (NY)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2342-8-16","article-title":"Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper","volume":"8","author":"Jensen MM","year":"2008","unstructured":"Jensen MM, J\u00f8rgensen JT, Binderup T, Kjaer A. Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008, 8:16. 10.1186\/1471-2342-8-16","journal-title":"BMC Med Imaging"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171169","article-title":"Dasatinib inhibits c-Src phosphorylation and prevents the proliferation of triple-negative breast cancer (TNBC) cells which overexpress syndecan-binding protein (SDCBP)","volume":"12","author":"Qian XL","year":"2017","unstructured":"Qian XL, Zhang J, Li PZ, et al.. Dasatinib inhibits c-Src phosphorylation and prevents the proliferation of triple-negative breast cancer (TNBC) cells which overexpress syndecan-binding protein (SDCBP). PLoS One. 2017, 12:e0171169. 10.1371\/journal.pone.0171169","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0287-3","article-title":"Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells","volume":"119","author":"Tian J","year":"2018","unstructured":"Tian J, Raffa FA, Dai M, et al.. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells. Br J Cancer. 2018, 119:1495-507. 10.1038\/s41416-018-0287-3","journal-title":"Br J Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040548","article-title":"Dasatinib treatment increases sensitivity to c-Met inhibition in triple-negative breast cancer cells","volume":"11","author":"Gaule P","year":"2019","unstructured":"Gaule P, Mukherjee N, Corkery B, et al.. Dasatinib treatment increases sensitivity to c-Met inhibition in triple-negative breast cancer cells. Cancers (Basel). 2019, 11:548. 10.3390\/cancers11040548","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060559","article-title":"Enhanced anticancer activity of nanoformulation of dasatinib against triple-negative breast cancer","volume":"11","author":"Bahman F","year":"2021","unstructured":"Bahman F, Pittal\u00e0 V, Haider M, Greish K. Enhanced anticancer activity of nanoformulation of dasatinib against triple-negative breast cancer. J Pers Med. 2021, 11:559. 10.3390\/jpm11060559","journal-title":"J Pers Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0404-5","article-title":"Population pharmacokinetic\/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor","volume":"55","author":"Khosravan R","year":"2016","unstructured":"Khosravan R, Motzer RJ, Fumagalli E, Rini BI. Population pharmacokinetic\/pharmacodynamic modeling of sunitinib by dosing schedule in patients with advanced renal cell carcinoma or gastrointestinal stromal tumor. Clin Pharmacokinet. 2016, 55:1251-69. 10.1007\/s40262-016-0404-5","journal-title":"Clin Pharmacokinet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-904306\/v1","article-title":"Dasatinib\/Celecoxib combination: a new hope in triple negative breast cancer treatment [PREPRINT, Version 1]","author":"Moussa NA","year":"2021","unstructured":"Moussa NA, Mohamed M, Helmy Wasfy M. Dasatinib\/Celecoxib combination: a new hope in triple negative breast cancer treatment [PREPRINT, Version 1]. Research Square. 2021, 10.21203\/rs.3.rs-904306\/v1","journal-title":"Research Square"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003468","article-title":"Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer","volume":"9","author":"Liu H","year":"2021","unstructured":"Liu H, Bai L, Huang L, et al.. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer. J Immunother Cancer. 2021, 9:e003468. 10.1136\/jitc-2021-003468","journal-title":"J Immunother Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19631","article-title":"Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways","volume":"8","author":"Garrido P","year":"2017","unstructured":"Garrido P, Shalaby A, Walsh EM, et al.. Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways. Oncotarget. 2017, 8:80568-88. 10.18632\/oncotarget.19631","journal-title":"Oncotarget"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann BD","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011, 121:2750-67. 10.1172\/JCI45014","journal-title":"J Clin Invest"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919897546","article-title":"Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer","volume":"12","author":"Canonici A","year":"2020","unstructured":"Canonici A, Browne AL, Ibrahim MF, et al.. Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer. Ther Adv Med Oncol. 2020, 12:10.1177\/1758835919897546","journal-title":"Ther Adv Med Oncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022791","article-title":"Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: a case report","volume":"99","author":"Pilalas D","year":"2020","unstructured":"Pilalas D, Koletsa T, Arsos G, et al.. Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: a case report. Medicine (Baltimore). 2020, 99:e22791. 10.1097\/MD.0000000000022791","journal-title":"Medicine (Baltimore)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6890-14-28","article-title":"alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies","volume":"14","author":"Koletsa T","year":"2014","unstructured":"Koletsa T, Stavridi F, Bobos M, et al.. alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. BMC Clin Pathol. 2014, 14:28. 10.1186\/1472-6890-14-28","journal-title":"BMC Clin Pathol"},{"key":"ref37","article-title":"Interaction between beta-catenin and EGFR expression by immunohistochemistry identifies prognostic subgroups in early high-risk triple-negative breast cancer","volume":"36","author":"Lakis S","year":"2016","unstructured":"Lakis S, Dimoudis S, Kotoula V, et al.. Interaction between beta-catenin and EGFR expression by immunohistochemistry identifies prognostic subgroups in early high-risk triple-negative breast cancer. Anticancer Res. 2016, 36:2365-78.","journal-title":"Anticancer Res"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1593\/neo.08314","article-title":"A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas","volume":"10","author":"Koletsa T","year":"2008","unstructured":"Koletsa T, Kostopoulos I, Charalambous E, Christoforidou B, Nenopoulou E, Kotoula V. A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia. 2008, 10:687-96. 10.1593\/neo.08314","journal-title":"Neoplasia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/176500-in-vitro-and-in-vivo-effects-of-docetaxel-and-dasatinib-in-triple-negative-breast-cancer-a-research-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:31Z","timestamp":1707509071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/176500-in-vitro-and-in-vivo-effects-of-docetaxel-and-dasatinib-in-triple-negative-breast-cancer-a-research-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.43534","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,15]]}}}